In some embodiments, therapeutically acceptable otic formulations are: The formulations disclosed herein alternatively encompass an otoprotectant agent in addition to the at least one active agent and/or excipients, including but not limited to such agents as antioxidants, alpha lipoic acid, calcium, fosfomycin or iron chelators, to counteract potential ototoxic effects that may arise from the use of specific therapeutic agents or excipients, diluents or carriers
All peptide use should be supervised by a qualified practitioner
In this observational cohort trial, 203 patients were enrolled and divided into two groups: one group, consisting of 101 patients, received oral doses of ALA (600 mg/day) and GLA (360 mg/day) together with a 6-week rehabilitation program
10.1126/scitranslmed.aap8914 133 WallaceB
10.1016/j.cbi.2011.02.029 88 SarmanH.BayramR.BenekS